In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific Looks to Next-Generation DES with Labcoat Deal

Executive Summary

Boston Scientific's unique two-drug strategy has propelled the company to a leadership position in drug-eluting stents with, according to some estimates, more than 50% of the market. Yet the company is not relying on the current configurations of or the current manufacturing approaches for its Taxus (using paclitaxel) and Promus (which employs everolimus) stents to sustain its position on top of this highly competitive product area. With its acquisition this month of Galway, Ireland-based Labcoat Ltd. (terms of which were not disclosed), BSC is laying the groundwork for technology that may well define its next generation of drug-eluting stents.
Advertisement

Related Content

Cappella: Can a New Twist On An Old Idea Solve the Bifurcation Challenge?
Cappella: Can a New Twist On An Old Idea Solve the Bifurcation Challenge?
Next-Generation Coronary Stent Start-Ups: Making a Difference in a Mature Market
Labcoat: Less is more in Next Generation Drug-Eluting Stents
Labcoat: Less is more in Next Generation Drug-Eluting Stents

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003198

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel